#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage

#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage

Submitted by admin on September 11, 2017 - 9:17am
Source: 
Endpoints
News Tags: 
ESMO
Eli Lilly
Pfizer
Novartis
abemaciclib
breast cancer
Headline: 
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage

Do Not Allow Advertisers to Use My Personal information